^
Association details:
| Biomarker: | CCL20 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | SB225002 (CXCR2 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway
Published date:
03/01/2023
Excerpt:
Furthermore, C-X-C motif chemokine receptor 2 (CXCR2) antagonist SB225002 enhanced the docetaxel (DTX) effects on tumor growth by decreasing BCSCs in CCL20 high-expressing tumors. These findings elucidated how CCL20 modulated the TME to promote cancer development, indicating a new therapeutic strategy by interfering with the interaction between PMN-MDSCs and BCSCs in breast cancer, especially in CCL20 high-expressing breast cancer.
DOI:
10.1038/s41392-023-01337-3
